Abstract
Molecular genetics is a powerful new tool for detection, diagnosis, evaluation of treatment, and understanding of the biology of malignant disease. The first malignant disease to be characterized by a specific cytogenetic aneuploid abnormality was chronic myelogenous leukemia (CML) which was first recognized in 1962 as an abnormal shortening of the long arm of either chromosome 21 or 22, the smallest chromosomes in the human genome. This cytogenetic abnormality was subsequently shown to represent not a loss of genetic material, but a pseudodiploid aneuploidy with a reciprocal translocation of chromosomal material from the long arms of chromosome 9 and 22. The discovery that the abl oncogene was located at the breakpoint on chromosome 9 allowed the molecular geneticists to identify the genetic material adjacent to the translocated material from chromosome 9 and because the breakpoint on chromosome 22 was variable but restricted to a small region, it was named the breakpoint cluster region (BCR). The BCR/abl gene has been found exclusively in leukemic cells from patients with CML. The somatic cells of the host are not involved and at least to date, every individual that has been found to have this gene has also had the disease CML. Approximately 15 % of CML patients lack the Philadelphia chromosome on cytogenetics. However, approximately half of these patients can be shown to have the BCR/abl neogene present as a masked translocation.
Keywords
- Reciprocal Translocation
- Acute Myeloblastic Leukemia
- Philadelphia Chromosome
- Blastic Phase
- Hematological Remission
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantar-jian HM, Trujillo JM (1992) Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 6: 500–505
Chang K-S, Wang G, Freireich EJ, Daly M, Naylor SL, Trujillo JM, Stass SA (1992) Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 79: 1802–1810
Lee M-S, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA (1992) Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79: 1920–1923
Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O’Brien S, Beran M, McCredie KB, Gutterman JU, Freireich EJ (1991) Intensive chemotherapy induction followed by interferon-α maintenance in patients with Philadelphia chromosome-positive chronic myelogeneous leukemia. Cancer 68: 1201–1207
Freireich EJ, Kantarjian H (eds) (1991) Therapy of Hematopoietic Neoplasia. Marcel Dekker Inc, New York
Freireich EJ, Lemak N (1991) Milestones in Leukemia Research and Therapy. Johns Hopkins University Press, Baltimore, Maryland
Freireich EJ, Marmont AM, McCulloch EA, Rees JKH, Reizenstein P, Wiernik PH (1990) New Approaches to the Treatment of Leukemia. In: Freireich EJ (ed). Springer-Verlag, Berlin
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag France
About this paper
Cite this paper
Freireich, E.J. (1994). The role of molecular genetics in medical oncology. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Cancer Treatment An Update. Springer, Paris. https://doi.org/10.1007/978-2-8178-0765-2_2
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0765-2_2
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0767-6
Online ISBN: 978-2-8178-0765-2
eBook Packages: Springer Book Archive